(CTMX) CytomX Therapeutics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CTMX) CytomX Therapeutics, Inc. Complete Analysis Pack
See the Bigger Picture
This CytomX Therapeutics, Inc. BCG Matrix helps you quickly see how the company’s products or business units may fit into the Stars, Cash Cows, Question Marks, and Dogs framework for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
2 Phase II programs
As of end-2025, CytomX Therapeutics, Inc. has two Phase II oncology assets, CX-2009 and CX-2029, and both are its most advanced wholly owned programs.
They are the clearest near-term value drivers because Phase II data can move valuation faster than earlier-stage assets, while still leaving room for upside if response rates improve.
In BCG terms, they fit Stars best: high growth potential with meaningful clinical maturity.
CX-2029, 4 cancers
CX-2029 is in Phase II across four cancers: squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma.
That 4-indication reach gives CytomX Therapeutics, Inc. its widest pipeline footprint and makes CX-2029 one of the clearest Star assets in the portfolio.
If data hold up, this breadth can drive more shots at value creation than a single-tumor asset.
CX-2009, breast cancer
CX-2009 is CytomX Therapeutics, Inc.’s Phase II antibody-drug conjugate for breast cancer, targeting CD166. ADCs are one of oncology’s fastest-growing classes, with a multi-billion-dollar global market and steady pipeline growth. If Phase II data stay positive, CX-2009 could move from development value toward commercial value.
2 BMS CTLA-4 programs
BMS-986249 is in Phase I/II and BMS-986288 is in Phase I, so CytomX Therapeutics, Inc. keeps a credible foot in checkpoint modulation while the Probody platform stays visible in immuno-oncology. Bristol Myers Squibb’s backing gives both programs strategic weight before any revenue is possible.
As of the latest public stage data, these are still precommercial assets, but they help preserve partner-led optionality in a market where BMS paid $2 billion upfront for the platform in 2014.
- Phase I/II and Phase I status
- Checkpoint modulation exposure
- Probody platform validation
- Partner-backed strategic value
Partner-led late-stage pipeline
CytomX’s Stars sit in its partner-led late-stage pipeline: the company’s highest-value assets are already in active human trials, so this is the main 2026 growth engine, not preclinical discovery. In BCG terms, CytomX is using partner funding and clinical data to turn programs like CX-904 into future market share. That is where value creation now happens.
- Active human trials, not discovery
- Main 2026 growth driver
- Partner-led risk sharing
- Clinical data converts to value
CytomX’s 2026 Growth Drivers: CX-2009 and CX-2029
CytomX Therapeutics, Inc.’s Stars are CX-2009 and CX-2029: both were in Phase II at end-2025, making them the company’s main 2026 value drivers. CX-2029 spans 4 tumor types, while CX-2009 targets CD166 in breast cancer. These assets have the best mix of growth potential and clinical maturity.
| Asset | Stage | Scope |
|---|---|---|
| CX-2029 | Phase II | 4 cancers |
| CX-2009 | Phase II | Breast cancer |
What is included in the product
Detailed Word Document
CytomX’s BCG Matrix maps its pipeline by growth and market share to pinpoint invest, hold, or divest priorities.
Editable Excel File
BCG Matrix for CytomX Therapeutics, Inc. for fast portfolio clarity and smarter resource allocation
Reference Sources
CytomX Therapeutics, Inc. Reference Sources provide a credible trail that speeds due diligence and supports faster, better decisions.
Cash Cows
6 pharma partners
CytomX Therapeutics, Inc. has 6 strategic pharma partners: AbbVie, Amgen, Bristol Myers Squibb, ImmunoGen, Pfizer, and Astellas. These alliances are the platform’s main recurring commercial output and can generate non-dilutive cash even without a marketed drug. In BCG terms, that makes this a steady Cash Cow asset: low capital burn, repeat deal value, and 6 external monetization channels.
Probody licensing platform
Probody is CytomX Therapeutics, Inc.'s core out-licensing engine, and it has been reused across more than 10 partnered programs, which is the classic Cash Cow setup in the BCG Matrix. In FY2025, the platform remained the mature asset that can keep generating collaboration value while funding newer pipeline bets.
Milestone and upfront economics
CytomX Therapeutics, Inc. does not sell approved products at scale; it earns cash mainly from partner upfronts, milestones, and research funding. That model can create repeatable inflows when programs advance, making deal cash the company’s closest Cash Cow. In a recent biotech peer set, milestone and collaboration revenue often drives most non-dilutive cash.
Partner-funded development
Partner-funded development fits Cash Cows because large-pharma deals absorb part of CytomX Therapeutics, Inc. R&D spend, so internal cash needs stay lower than in a fully self-funded pipeline. The value is steadier than a single launch, but it still depends on milestone progress, data readouts, and partner funding decisions.
- Lower internal R&D burn
- Shared program risk
- Milestone-driven cash flow
- Less launch-style volatility
This makes CytomX Therapeutics, Inc. more capital efficient, but not fully insulated from collaboration setbacks. If a partner slows a program, the cash-cow profile weakens fast.
Non-dilutive revenue stream
CytomX Therapeutics, Inc. uses a collaboration model that brings in cash without building a drug factory or a sales force, so overhead stays lighter than a marketed oncology company. That makes partner-funded revenue its main recurring cash engine at end-2025. In BCG terms, it fits Cash Cows because the model can keep producing value with limited capital drag.
Partner deals fund R&D
No commercial launch costs
Lower overhead than peers
CytomX’s Partner Model Keeps Cash Flowing
In FY2025, CytomX Therapeutics, Inc. still fits a Cash Cow mainly through its partner model: 6 pharma alliances and more than 10 Probody programs have kept non-dilutive cash flowing without a large sales force.
| Metric | FY2025 |
|---|---|
| Strategic partners | 6 |
| Probody partnered programs | 10+ |
| Cash source | Upfronts, milestones, research funding |
This makes the platform a mature, low-burn asset that can fund newer bets, but cash flow still depends on partner progress and milestone timing.
What You See Is What You Get
CytomX Therapeutics, Inc. Reference Sources
You're previewing the exact CytomX Therapeutics, Inc. BCG Matrix report you’ll receive after purchase. No demo pages or placeholder content—just the full, ready-to-use document. Once purchased, the same file is instantly available for download, editing, or presentation. It’s built for clear strategic review and professional use.
Dogs
0 approved drugs
As of FY2025, CytomX Therapeutics, Inc. had 0 approved drugs and no marketed oncology brand, so it had no mature commercial franchise to defend. That makes the BCG Dog label fit only in a narrow sense: the company still lacks a low-growth legacy product base, not a fading cash cow. In 2025, revenue was still driven by collaboration payments, not product sales.
0 product sales
CytomX Therapeutics, Inc. has 0 product sales, so this is a clear Dogs asset in the BCG Matrix. The Company’s revenue still comes from collaboration payments and R&D activity, not commercial drug sales, so it has no self-sustaining sales engine in the portfolio.
No commercial market share
CytomX Therapeutics, Inc. is still pre-commercial, so market share is not meaningful yet; there is no branded oncology product on the market to measure. In FY2025, it had no commercial drug sales, which keeps it out of true cash-cow territory and far from a Dog-to-Cow shift. Until launch, this stays a development-stage asset, not a share-led business.
Pre-commercial operating model
CytomX Therapeutics, Inc. fits the Dog quadrant here because its model is still pre-commercial: it posted $15.7 million of revenue in FY2025, while R&D stayed high at about $88.5 million, so cash burn still dominates economics. With no approved product driving repeat sales, returns remain weak and unstable.
The latest filings also show a loss-making base, with FY2025 net loss near $86.3 million and cash, cash equivalents, and marketable securities around $137 million at year-end. That mix signals a portfolio that is still buying time in clinic, not yet earning durable market share.
- FY2025 revenue: $15.7 million
- FY2025 R&D: about $88.5 million
- FY2025 net loss: about $86.3 million
- Year-end liquidity: about $137 million
Legacy pipeline risk
For CytomX Therapeutics, Inc., legacy pipeline risk is a real Dog because FY2025 still showed a clinical-stage model with no approved-product cash engine, so any program that misses proof of concept can turn into stranded R&D spend. That matters most when value depends on trial wins, since underperforming or stopped assets stop creating optionality and keep burning cash.
- Clinical-stage assets can become sunk cost.
- Failed proof of concept cuts future value.
- Dogs are weak, discontinued programs.
CytomX: Cash Runway, No Commercial Engine
CytomX Therapeutics, Inc. fits Dogs only in a limited BCG sense: FY2025 revenue was $15.7 million, but it had no approved drug or marketed product, so there is no real cash cow to defend. The model stayed pre-commercial, with about $88.5 million in R&D and an FY2025 net loss near $86.3 million. Year-end cash, cash equivalents, and marketable securities were about $137 million, showing runway but no durable sales engine.
| Metric | FY2025 |
|---|---|
| Revenue | $15.7M |
| R&D | $88.5M |
| Net loss | $86.3M |
| Liquidity | $137M |
Question Marks
CX-2043
CX-2043 is a conditionally activated ADC targeting EPCAM, and it sits earlier in CytomX Therapeutics, Inc.’s pipeline than the Phase II assets. That makes it a Question Mark in the BCG Matrix: high upside, but clinical validation is still missing. In 2025, CytomX Therapeutics, Inc. reported a cash balance that supports development, but CX-2043 still needs clear human data to prove it can move toward a Star.
CX-904
CX-904 is CytomX Therapeutics, Inc.’s conditionally activated EGFR program for solid tumors, and EGFR is one of oncology’s biggest targets. But the asset still must prove that it can beat older EGFR drugs on efficacy and safety, which keeps it in the Question Mark bucket. The issue is clear: big market, but still unproven differentiation.
BMS-986249
BMS-986249 is still in Phase I/II for metastatic melanoma, so it has human data but not enough proof to rank as a Star in CytomX Therapeutics, Inc.'s BCG view.
Its value case still hinges on the next clinical readout, safety and response data, and Bristol Myers Squibb’s partner call on whether to push it further.
Until clearer efficacy data land, it stays a Question Mark: real upside, but no durable commercial case yet.
BMS-986288
BMS-986288 is a Phase I solid-tumor program, so in a BCG view it sits in the Question Mark bucket: high upside, but still unproven and cash hungry. Early human trials often burn millions before any clear value step-up, and CytomX Therapeutics, Inc. will need clean safety and response data to justify more spend.
If Phase I signals are strong, BMS-986288 could move toward a Star candidate; if not, it may be cut before it uses more capital. That risk matters because CytomX Therapeutics, Inc. reported no product revenue in its 2025 results and stayed dependent on pipeline execution.
- Phase I only; no value proof yet
- High cash burn risk before efficacy
- Success could lift it to Star status
- Weak data could end the program
Next Probody entrants
Future CytomX Probody entrants stay in Question Mark status because they have no proven clinical activity yet, so they need capital before they can move toward Star status. As of the latest public pipeline view, the company’s next-wave assets still sit behind early clinical readouts, with 2 visible lead programs, CX-904 and CX-2051, carrying the platform risk. In BCG terms, that means high upside, but also a high burn rate until human data de-risks the platform.
- Unproven assets stay Question Marks until data
- 2 lead programs are still clinical-stage
- More spending is needed before Star status
CytomX’s Early Pipeline Holds Upside, but Proof Is Still Ahead
CytomX Therapeutics, Inc.’s Question Marks are its early programs CX-2043, CX-904, BMS-986249, and BMS-986288: each has upside, but none has enough human proof yet to rank as a Star. In 2025, CytomX Therapeutics, Inc. reported no product revenue and cash to keep funding trials, so value still hinges on the next readouts.
| Asset | Stage | BCG |
|---|---|---|
| CX-2043 | Early clinical | Question Mark |
| CX-904 | Early clinical | Question Mark |
| BMS-986249 | Phase I/II | Question Mark |
| BMS-986288 | Phase I | Question Mark |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.